Professor Oliver Hanemann

Professor Oliver Hanemann

Chair in Clinical Neurobiology

Peninsula Medical School (Faculty of Health)

Professor Oliver Hanemann can be contacted through arrangement with our Press Office, to speak to the media on these areas of expertise.
  • Cancer
  • Neurofibromatosis
  • Motor neurone disease
  • Oncology
  • Brain tumour
  • Neurology
  • Neuroscience
  • Clinical trials
  • Experimental methods
  • Laboratory methods
  • Medical/pathological research
  • Quantitative research


Associate Head (Research) Peninsula Medical School
Chair of Clinical Neurobiology
Plymouth University Peninsula Medical School
Neurology Consultant
University Hospitals Plymouth Hospital NHS Trust 


I trained at Medical School in Hamburg, Glasgow, Johns Hopkins and Harvard. After a DFG research fellowship in molecular neurobiology, in which I cloned the myelin protein PMP22 I was neurology registrar at Medical School in Duesseldorf with Prof Freund. During that period I participated in resolving gene-defect and pathogenesis of the most frequent hereditary neuropathy CMT1A, became lecturer for Neurology and Neurobiology and honorary consultant at that department in 1998 and started work on benign glial tumours. From 2000 I was consultant incl. clinical lead and senior lecturer at the medical school in Ulm continuing my work on benign glia tumours and neuropathies focussing more on motor neuropathies. During that time I was also trained as a medical geneticist. In 2005 I became chair of clinical neurobiology at the Peninsula medical school establishing clinical neurobiology research and administering different independent researcher groups. I successfully bridge basic and clinical sciences. I have been Associate Medical Director for R&D Plymouth Hospital NHS Trust and and Academic lead department of Neurology PHNT 
I was founding director of the Institute for Translational and Stratified Medicine where my remit was to champion research across traditional boundaries and focus on world-leading research. I was Associate Dean Research 2015-2017. Currently I am Associate Head (Research) Peninsula Medical School and lead the Brain Tumour Centre of Excellence at the University of Plymouth

Professional membership


Roles on external bodies

Nationally I am neurology lead in the Peninsula Neuro-oncology network, member BNOS council and DeNDRON, (currently research director MND in the SW), I was member of scientific advisory boards in multiple organisations (currently GOSHH),. I am reviewer for more than 20 international journals including Brain, Cancer Res, Oncogene Nature Communications and Human Mol Gen, and reviewer for a variety of granting agencies incl Wellcome, MRC, CR-UK and DFG. I am editor of Cancer Letters.


Staff serving as external examiners

Involved in research SSU's, case units, lectures
External PhD examiner at: University of Exeter, University of Portsmouth, University Cardiff, Queen Mary University, UCL, University Jena, University Ulm 


Research interests

My own focus is on neuromuscular disease esp. motor neuron disease and neurooncology. I supervised more than 30 PhD students quite a few finished with distinction and started a career in academia. Our current work on motor neuron disease is mainly clinical and includes genotype-phenotype analysis and clinical trials. In neurooncology we focus on cell biology studies to find and validate new therapeutic targets as there is a great medical need to find new treatments. Following our aim to work translational I also look after many patients with these diseases as a honorary consultant. 
My current h-index is 56

Research degrees awarded to supervised students

The Brain Tumour Centre comprises three research groups with roughly 30 staff including PhD students

Grants & contracts

Over 4 Million £ previously excluding FEC. Currently Brain Tumour Research centre grant, Children's Tumour Foundation


Total 168, h-index: google scholar 56, total citation over 10826
Selected recent highly cited publications including few older key publications
1. Spreyer, G. Kuhn, C.O. Hanemann, C. P. Gillen, R. Kuhn, G. Lemke, H.W. Müller, (1991) Axon regulated expression of a Schwann cell mRNA homologous to a growth arrest specific gene, EMBO Journal 10 3661-68
2. Timmerman V., Nelis E, Van Hul W. Nieuwenhuijsen B.W., Chen K.L., Ben Othman K., Cullen B., Leachz R.J., Hanemann C.O., Dejonghe P., Raymakers P., van Ommen G.-J.B., Martin J.J., Müller H.W., Vance J.M., Fischbeck K.H. and Van Broeckhoven C. (1992), The peripheral myelin protein gene pmp22 is Contained within the Charcot-Marie-Tooth disease type 1A duplication, Nature Genetics 1 171-175
3. Matsunami N., Smith B., Ballard L., Lensch M.W., Robertson M., Albertson H., Hanemann C.O., Müller H.W., et al. (1992), Peripheral myelin protein-22 gene maps in the duplication in chromosome 17 p11.2 associated with Charcot-Marie-Tooth 1A, Nature Genetics 1 176-179
4. European Study Group on Interferon ß-1b in Secondary progressive MS....CO Hanemann..... (1998) Placebo-controlled multicentre randomised trial of interferon ß-1b in treatment of secondary progressive multiple sclerosis. The Lancet 352 , 1491-97
5. CO Hanemann, Müller HW (1998). Pathogenesis of CMT1A neuropathy, Trends in Neuroscience 21: 282-286
6. CO Hanemann, D D´Urso, AAWM Gabreels:Festen, HW Müller (2000). Altered distribution of PMP22 in nerve biopsies from CMT1A patients with different PMP22 mutations, Brain 123:1001-6
7. Sperfeld AD, Hein C, Schröder JM, Ludolph AC Hanemann CO (2002) Occurrence and characterisation of peripheral nerve involvement in Neurofibromatosis Type 2 Brain 125:996-1004
8. Schulze K, Hanemann CO*, Müller HE, Hanenberg H (2002) Transduction of wt-merlin into human schwannomma cells decreases schwannoma cell growth and induces apoptosis. Human Molecular Genetics 11 (1) 69-76 *Corresponding author
9. Sperfeld AD, Karitzky J, Schreiber H, Brummer D, Häußler J , Ludolph AC, Hanemann CO. (2002) X-linked bulbospinal neuronopathy Kennedy: presence of known and unknown clinical features and electrophysiological investigation in 34 cases, Archives of Neurology (now JAMA Neurology) 59:1921-6
10. Hanemann CO (2008) Magic but treatable? Tumours due to loss of Merlin, Brain, 131:606-15
11. Li W, You L, Cooper J, Schiavon G, Zhou L, Ishii R, Pepe-Caprio A, Giovannini M, Long SB, Erdjument-Bromage H, Hanneman CO, Zhou P, Tempst P & Giancotti F (2010). Merlin/NF2 Suppresses Tumorigenesis by Inhibiting the E3 Ubiquitin Ligase CRL4-DCAF1 in the Nucleus, Cell, 140:477-90
12. S Ammoun and CO Hanemann (2011) New Therapeutic Approaches for merlin deficient tumours, emerging molecular targets, Nature Reviews Neurology, 7(7):392-9.
13. Sher, CO Hanemann, PA Karplus, and AP Bretscher (2012). The tumor suppressor merlin controls growth in its open state and is converted to an inactive closed state by phosphorylation, Dev Cell 22(4):703-5.
14. Ammoun S, L Provenzano, L Zhou, M Barczyk, K Evans, DA Hilton, S Hafizi and CO Hanemann Axl/Gas6/NFkB signalling in schwannoma pathological proliferation, adhesion and survival, Oncogene doi: 10.1038/onc.2012.587
15. Doddrell RD, Dun XP, Shivane A, Feltri ML, Wrabetz L, Wegner M, Sock E, Hanemann CO, Parkinson DB (2013). Loss of SOX10 function contributes to the phenotype of human Merlin-null schwannoma cells. Brain 136:549-63
16. Morrison KE, Dhariwal S, Hornabrook R, et al. (2013) Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trial Lancet Neurol. 2013 Apr;12(4):339-45
17. Schulz A, Baader SL, Niwa-Kawakita M, Jung MJ, Bauer R, Garcia C, Zoch A, Schacke S, Hagel C, Mautner VF, Hanemann CO, Dun XP, Parkinson DB, Weis J, Schröder JM, Gutmann DH, Giovannini M, Morrison H. (2013) Merlin isoform 2 in neurofibromatosis type 2-associated polyneuropathy Nat Neurosci. 2013 Apr;16(4):426-33
18. SR. Plotkin, JO Blakeley, E Dombi, MJ. Fisher, CO Hanemann, KS Walsh, PL Wolters, BC Widemann (2013) Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) International Collaboration: Guidelines for Clinical Trials, Neurology, 9;81(21 Suppl 1):S1-5..
19. BC Widemann, JO Blakeley, E Dombi, MJ Fisher, CO Hanemann, KS Walsh, PL Wolters, SR Plotkin (2013), Conclusions and Future Directions for the REiNS International Collaboration, Neurology, 19;81(21 Sup 1):S41-4
20. Hilton DA and Hanemann CO (2014) Schwannomas and their pathogenesis, Brain Pathology epub doi: 10.1111/bpa.12125
21. RE. Ferner, A Shaw, DG Evans, D McAleer, D Halliday, A Parry, F Lucy Raymond, J Durie-Gair, CO Hanemann, Rl Hornigold, P Axon, JF Golding Longitudinal evaluation of quality of life in 288 patients with neurofibromatosis 2, J Neurology DOI 10.1007/s00415-014-7303-1
22. Wei Li, J Cooper, L Zhou, C Yang, H Erdjument-Bromage, D Zagzag, M Snuderl, M Ladanyi, CO Hanemann, P Zhou, MA. Karajannis and FG Giancotti ( 2014) Merlin/NF2-loss Driven Tumorigenesis Linked to CRL4DCAF1-Mediated Inhibition of the Hippo Pathway Components Lats1 and 2 in the Nucleus, Cancer Cell 14;26(1):48-60
23. KA. Rauen, SM Huson, E Burkitt-Wright, GD Evans, S Farschtschi, R Ferner, DH Gutmann, CO Hanemann, B Kerr, E Legius, L Parada, M Patton, J Peltonen, N Ratner, VM Riccardi, T Van der Vaart, M Vikkula, DH Viskochil, M Zenker and M Upadhyaya (2015) Recent Developments in Neurofibromatoses and RASopathies: Management, Diagnosis and Current and Future Therapeutic Avenues, Am J Med Gen, 167A(1):1-10
24. CJ McDermott, PJ Shaw, T Stavroulakis, SJ Walters, A Al-Chalabi, S Chandran, F Crawley, D Dick, C Donaghy, P Eames, M Fish, C Gent, G Gorrie, H Hamdalla, CO Hanemann, et al. (2015) Gastrostomy in patients with amyotrophic lateral sclerosis (ProGas): a prospective cohort study Lancet Neurology 14, 702-709
25. CJ McDermott,MJ Bradburn, C Maguire, CL Cooper, WO Baird, SK Baxter; SC Bourke; I Imam; A Bentley; J Ealing; M Elliott; CO Hanemann, et al. (2015) Safety and effi cacy of diaphragm pacing in patients with respiratory
insuffi ciency due to amyotrophic lateral sclerosis (DiPALS): a multicentre, open-label, randomised controlled trial. Lancet Neurology 134(9) 883-892 26. Button RW, Lin F, Ercolano E, Vincent JH, Hu B, Hanemann CO, Luo S Artesunate induces necrotic cell death in schwannoma cells. Cell Death Dis. 2014 Oct 16;5:e1466. doi: 10.1038/cddis.2014.434.
27. Zhou L, Lyons-Rimmer J, Ammoun S, Müller J, Lasonder J, Sharma V, Ercolano E, Hilton D, Taiwo I, Barczyk M Hanemann CO (2015)The scaffold protein KSR1, a novel therapeutic target for the treatmentbof merlin defiient tumousr, Oncogene, doi: 10.1038/onc.2015.404.
28. Hexter A, Jones A, Joe H, Heap L, Smith MJ, Wallace AJ, Halliday D, Parry A, Taylor A, Raymond L, Shaw A, Afridi S, Obholzer R, Axon P, King AT; English Specialist NF2 Research Group, Friedman JM, Evans DG Clinical and molecular predictors of mortality in neurofibromatosis 2: a UK national analysis of 1192 patients J Med Genet. 2015 Oct;52(10):699-705. doi: 10.1136/jmedgenet-2015-103290. Epub
29. Hanemann CO, Blakeley JO, Nunes FP, Robertson K, Stemmer-Rachamimov A, Mautner V, Kurtz A, Ferguson M, Widemann BC, Plotkin SR, Evans DG, Ferner R, Carroll SL, Korf B, Wolkenstein P, Knight P (2016) Current status and recommendations for biomarkers in Neurofibromatosis 1, Neurofibromatosis 2 and schwannomatosis, Neurology Aug 16;87(7 Suppl 1):S40-8.
30. Provenzano L, Ryan Y, Hilton D ,Rigby-Jones R, Hanemann CO, and Ammoun S (2017) Cellular Prion Protein (PrPC) Promotes Schwannoma Tumourigenesis via 37/67kDa Laminin Receptor, Oncogene doi: 10.1038/onc.2017.200
31. Cooper J, Zhou L, Ojeda V, Moulick K, de Stanchina E, Poirier JT, Rudin CM, Hanemann CO, Giancotti FG (2017) Combined Inhibition of NEDD8-Activating Enzyme and mTOR Suppresses NF2 Loss-Driven Tumorigenesis Mol Can Ther doi: 10.1158/1535-7163.MCT-16-0821
32. Button RW, Roberts SL, Willis TL, Hanemann CO, Luo S Accumulation of autophagosomes confers cytotoxicity J Biol Chem. 2017 Jul 3. pii: jbc.M117.782276. doi: 10.1074/jbc.M117.782276.
33. Stepanova DS, Semenova G, Kuo YM, Andrews AJ, Ammoun S, Hanemann CO, Chernoff J An essential role for the tumor suppressor Merlin in regulating fatty acid synthesis Cancer Res. 2017 Jul 20. pii: canres.2834.2016. doi: 10.1158/0008-5472.CAN-16-2834
34. K Bassiri, S Ferluga, V Sharma, E Lasonder, CO Hanemann (2017) Phosphoproteomic Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 Overexpression, EBiomedicine 16:76-86
35. Collard G, Tarpey P Kurbalova N et al. (2018) An integrated genomic analysis of anaplastic meningioma identifies prognostic molecular signatures, Scientific Reports 10;8(1):13537
36. Milinis K … Hanemann CO …et al Understanding the impact of spasticity in amyotrophic lateral sclerosis/motor neurone disease upon quality of life: development, validation and use of Spasticity Index – ALS (SI-ALS), Acta Neurol Scand. 2018 Feb 21. doi: 10.1111/ane.12910
37. van Eijk RPA, Jones AR, Sproviero W, Shatunov A, Shaw PJ, Leigh PN, Young CA, Shaw CE, Mora G, Mandrioli J, Borghero G, Volanti P, Diekstra FP, van Rheenen W, Verstraete E, Eijkemans MJC, Veldink JH, Chio A, Al-Chalabi A, van den Berg LH, van Es MA; For UKMND-LiCALS and LITALS Study Group Meta-analysis of pharmacogenetic interactions in amyotrophic lateral sclerosis clinical trials.Neurology. 2017 Oct 31;89(18):1915-192
38. S Suppiah, F Nassiri, I Dunn, CO Hanemann ..G Zadeh et al A Molecular and translational advances in meningioma, Neuro-oncology, 2019 Jan 14;21(Supplement_1):i4-i17. doi: 10.1093/neuonc/noy178
39. Nassiri F, Price B, Shehab A et al. Life after surgical resection of a meningioma: a prospective cross-sectional study evaluating health-related quality of life. Neuro-Oncolology. 2019 Jan 14;21(Supplement_1):i32-i43. doi: 10.1093/neuonc/noy152.
40. Huang RY, Bi WL, Griffith B, Kaufmann TJ et al. Imaging and diagnostic adavances for intracranial meningioma. Neuro-Oncology 2019 Jan 14;21(Supplement_1):i44-i61. doi: 10.1093/neuonc/noy143
41. Brastianos PK, Galanis E, Butowski N et al. Advances for in multidisciplinary therapy for meningiomas. Neuro-Oncology. 2019 Jan 14;21(Supplement_1):i18-i31. doi: 10.1093/neuonc/noy136
42. B Emmanouil, R Houston, A May, JD Ramsden, CO Hanemann, D Halliday, A Parry, S Mackeith Progression of hearing loss in Neurofibromatosis type 2 according to genetic severity, Laryngoscope. 2018 Nov 19. doi: 10.1002/lary.27586
43. Dunn J, Ferluga S, Sharma V, Futschik M, Hilton DA, Adams CL, Lasonder E, Hanemann CO. Proteomic analysis discovers the differential expression of novel proteins and phosphoproteins in meningioma including NEK9, HK2 and SET and deregulation of RNA metabolism EBioMedicine. 2018 Dec 26. pii: S2352-3964(18)30625-X. doi: 10.1016/j.ebiom.2018.12.048
Ammoun Sylwia, Hilton David, Gareth Evans, Streeter Adam, Hayward Chris, Hanemann C Oliver, 2019 Phase 0 trial investigating the intra-tumoural concentration and activity of Sorafenib in NF2, JNNP, doi: 10.1136/jnnp-2018-319713
45. Halliday D, Emmanouil B, Vassallo G, Lascelles K, Nicholson J, Chandratre S, Anand G, Wasik M, Pretorius P, Evans DG, Parry A; English NF2 research group. Trends in phenotype in the English paediatric neurofibromatosis type 2 cohort stratified by genetic severity Clin Genet. 2019 Apr 16. doi: 10.1111/cge.13551
46. Claire L Adams, Emanuela Ercolano, Sara Ferluga , Agbolahan Sofela, Foram Dave, Caterina Negroni, Kathreena M Kurian, David A Hilton and C Oliver Hanemann A rapid robust method for subgrouping non-NF2 meningiomas according to genotype and detection of lower levels of M2 macrophages in AKT1 E17K mutated tumours, Int J Mol Sciences 2020 Feb 13;21(4)
47. M Palomo-Irigoyen, E Perez-Andres, M Iruarrizaga-Lejarreta, M Varela-Rey, A Barreira-Manrique, M Tamayo-Caro, N Beitia, D Medrano, J Jose Lozano, S Okawa, JL. Lavin, N Martin-Martin, JD Sutherland, D Fernandez-Ramos, V Guitierez de Juan, M Gonzalez-Lopez, N Macias-Camara, D Mosen-Ansorena, L Laraba, CO Hanemann, et al. RNA-binding protein HuR/ELAVL1 drives Malignant Peripheral Nerve Sheath Tumour growth and metastasis, J Clin Invest 2020 Jun 15;130379. doi: 10.1172/JCI130379
48. C Negroni, DA Hilton, E Ercolano, C L. Adams, KM. Kurian, Daniele Baiz, and C. O Hanemann GATA-4, a potential novel therapeutic target for high-grade meningioma, regulates miR-497, a potential novel circulating biomarker for high-grade meningioma, EBioMedicine 2020 Sep;59:102941. doi: 10.1016/j.ebiom.2020.102941
49. J Lyons Rimmer, E Ercolano, D Baiz, M Makhija, A Berger, T Sells, S Stroud, D Hilton, CL Adams and CO Hanemann The potential of MLN3651 in combination with selumetinib as a treatment for Merlin-deficient meningioma, Cancers 2020 Jun 30;12(7):1744. doi: 10.3390/cancers12071744
50. Dunn J, Lenis VP, Hilton DA, Warta R, Herold-Mende C, Hanemann CO, Futschik ME Integration and Comparison of ranscriptomics and Protemic Data for Meningioma, Cancers 2020 Nov 5;12(11):E3270. doi: 10.3390/cancers12113270
51. Sofela AA, Hilton DA, Ammoun S, Baiz D, Adams CL, Ercolano E, Jenkinson MD, Kurian KM, Teo M, Whitfield PC, Sahm F, Hanemann CO Fibulin-2: A Novel Biomarker for differentiating grade II from grade I meningioma Int J Mol Sci. 2021 Jan 8;22(2):560. doi: 10.3390/ijms22020560
52. Young CA, McDermott CJ, Williams TL, Ealing J, Majeed T, Al-Chalabi A, Dick DJ, Talbot K, Harrower T, Pinto A, Hanemann CO, Burke G, Roberts R, Mills RJ, Tennant A; TONiC study group. Measuring coping in people with amyotrophic lateral sclerosis using Coping Index-ALS: A patient derived, Rasch compliant scale J Neurol Sci. 2020 Dec 29;421:117285. doi: 10.1016/j.jns.2020.117285
53. C Bettegowda, M Upadhayaya, DG Evans, A Kim, D Mathios and CO Hanemann for the REiNS International Collaboration, Genotype-Phenotype correlations in neurofibromatosis and their potential clinical use, Neurology 2021 Aug 17;97(7 Suppl 1):S91-S98. doi: 10.1212/WNL.0000000000012436.
54. Humman endogenous retrovirus type K promotes proliferation and confers sensitivity to anti-retroviral drugs in Merlin-negative schwannoma and meningioma Maze EA, Agit B, Reeves S, Hilton DA, Parkinson DB, Laraba L, Ercolano E, Kurian KM, Hanemann CO, Belshaw RD, Ammoun S. Cancer Res. 2022 Jan 15;82(2):235-247. doi: 10.1158/0008-5472.
55. Plotkin SR, Messiaen L, Legius E, Pancza P, Avery RA, Blakeley JO, Babovic-Vuksanovic D, Ferner R, Fisher MJ, Friedman JM, Giovannini M, Gutmann DH, Hanemann CO, et al. International Consensus Group on Neurofibromatosis Diagnostic Criteria (I-NF-DC); Huson SM, Wolkenstein P, Evans DG. Updated diagnosyic criteria and nomenclature for neurofibroamtoais type 2 and schwannomatosis: An intrenational consensus recommendation. Genet Med. 2022 Sep;24(9):1967-1977. doi: 10.1016/j.gim.2022.05.007
56. Laraba L, Hillson L, de Guibert JG, Hewitt A, Jaques MR, Tang TT, Post L, Ercolano E, Rai G, Yang SM, Jagger DJ, Woznica W, Edwards P, Shivane AG, Hanemann CO, Parkinson DB. Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma Brain. 2023 Apr 19;146(4):1697-1713. doi: 10.1093/brain/awac342
57. LL. van de Weijer, E Ercolano, T Zhang, M Shah, MC Banton, J Na, C. Adams, D Hilton, KM Kurian & CO Hanemann A novel patient-derived meningioma spheroid model as a tool to study and treat epithelial-to mesenchymal transition (EMT) in meningiomas, Acta Neuopathologica Com 2023;11:198. doi: 10.1186/s40478-023-01677-9
58. LR. Diaz, J Gil-Ranedo, KJ Jaworek, N Nsek, JP Marques, E Costa, DA Hilton, H Bieluczyk, O Warrington, CO Hanemann, ME Futschik, T Bossing and CS Barros Ribogenesis boost controlled by HEATR1-MYC interplay promotes transition into brain tumour growth, EMBO Rep 2024 Jan 15. doi: 10.1038/s44319-023-00017-1
Conference Papers
Presentations and posters
Other Publications